Scopolamine (hyoscine) for preventing and treating motion sickness (Review)

Spinks A, Wasiak J

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2011, Issue 6

http://www.thecochranelibrary.com
### TABLE OF CONTENTS

- **HEADER** .................................................................................................................. 1
- **ABSTRACT** .................................................................................................................. 1
- **PLAIN LANGUAGE SUMMARY** .................................................................................... 2
- **BACKGROUND** ......................................................................................................... 2
- **OBJECTIVES** .............................................................................................................. 3
- **METHODS** ................................................................................................................. 3
- **RESULTS** .................................................................................................................... 5
- **DISCUSSION** .............................................................................................................. 8
- **AUTHORS’ CONCLUSIONS** ....................................................................................... 9
- **ACKNOWLEDGEMENTS** ............................................................................................ 9
- **REFERENCES** ............................................................................................................. 9
- **CHARACTERISTICS OF STUDIES** ........................................................................... 12
- **APPENDICES** ........................................................................................................... 23
  - Analysis 1.1. Comparison 1 Prevention of sickness symptoms (nausea), Outcome 1 Scopolamine vs placebo. ......................................................................................... 24
  - Analysis 1.2. Comparison 1 Prevention of sickness symptoms (nausea), Outcome 2 Scopolamine vs scopolamine + ephedrine. ................................................................. 25
  - Analysis 2.1. Comparison 2 Prevention of vomiting, Outcome 1 Scopolamine vs scopolamine + ephedrine. ................................................................. 25
  - Analysis 3.1. Comparison 3 Adverse event: drowsiness, Outcome 1 Scopolamine vs placebo. ......................................................................................... 26
  - Analysis 4.1. Comparison 4 Adverse events: blurred vision, Outcome 1 Scopolamine vs placebo. ......................................................................................... 26
- **DATA AND ANALYSES** ............................................................................................. 26
- **FEEDBACK** ............................................................................................................... 28
- **WHAT’S NEW** .......................................................................................................... 29
- **HISTORY** .................................................................................................................. 29
- **CONTRIBUTIONS OF AUTHORS** .......................................................................... 30
- **DECLARATIONS OF INTEREST** ............................................................................. 30
- **INDEX TERMS** ......................................................................................................... 30
Scopolamine (hyoscine) for preventing and treating motion sickness

Anneliese Spinks2, Jason Wasiak1

1Victorian Adult Burns Service and School of Public Health and Preventative Medicine, Monash University, Alfred Hospital, Melbourne, Australia. 2School of Medicine, Griffith University, Meadowbrook, Australia

Contact address: Jason Wasiak, Victorian Adult Burns Service and School of Public Health and Preventative Medicine, Monash University, Alfred Hospital, Commercial Road, Prahran, Melbourne, Victoria, 3181, Australia. J.Wasiak@alfred.org.au.
jwasiak1971@gmail.com.

Editorial group: Cochrane Ear, Nose and Throat Disorders Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 6, 2011.
Review content assessed as up-to-date: 13 April 2011.


Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Motion sickness, the discomfort experienced when perceived motion disturbs the organs of balance, may include symptoms such as nausea, vomiting, pallor, cold sweats, hypersalivation, hyperventilation and headaches. The control and prevention of these symptoms has included pharmacological, behavioural and complementary therapies. Although scopolamine (hyoscine) has been used in the treatment and prevention of motion sickness for decades, there have been no systematic reviews of its effectiveness.

Objectives
To assess the effectiveness of scopolamine versus no therapy, placebo, other drugs, behavioural and complementary therapy or two or more of the above therapies in combination for motion sickness in persons (both adults and children) without known vestibular, visual or central nervous system pathology.

Search methods
We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL); PubMed; EMBASE; CINAHL; Web of Science; BIOSIS Previews; Cambridge Scientific Abstracts; ICTRP and additional sources for published and unpublished trials. The date of the most recent search was 14 April 2011.

Selection criteria
All parallel-arm, randomised controlled trials (RCTs) focusing on scopolamine versus no therapy, placebo, other drugs, behavioural and complementary therapy or two or more of the above therapies in combination. We considered outcomes relating to the prevention of onset or treatment of clinically-defined motion sickness, task ability and psychological tests, changes in physiological parameters and adverse effects.

Data collection and analysis
Two authors independently extracted data from the studies using standardised forms. We assessed study quality. We expressed dichotomous data as odds ratio (OR) and calculated a pooled OR using the random-effects model.
Main results

Of 35 studies considered potentially relevant, 14 studies enrolling 1025 subjects met the entry criteria. Scopolamine was administered via transdermal patches, tablets or capsules, oral solutions or intravenously. Scopolamine was compared against placebo, calcium channel antagonists, antihistamine, methscopolamine or a combination of scopolamine and ephedrine. Studies were generally small in size and of varying quality.

Scopolamine was more effective than placebo in the prevention of symptoms. Comparisons between scopolamine and other agents were few and suggested that scopolamine was superior (versus methscopolamine) or equivalent (versus antihistamines) as a preventative agent. Evidence comparing scopolamine to cinnarizine or combinations of scopolamine and ephedrine is equivocal or minimal.

Although sample sizes were small, scopolamine was no more likely to induce drowsiness, blurring of vision or dizziness compared to other agents. Dry mouth was more likely with scopolamine than with methscopolamine or cinnarizine.

No studies were available relating to the therapeutic effectiveness of scopolamine in the management of established symptoms of motion sickness.

Authors’ conclusions

The use of scopolamine versus placebo in preventing motion sickness has been shown to be effective. No conclusions can be made on the comparative effectiveness of scopolamine and other agents such as antihistamines and calcium channel antagonists. In addition, we identified no randomised controlled trials that examined the effectiveness of scopolamine in the treatment of established symptoms of motion sickness.
tors such as the eyes, the vestibular system, and mechanoreceptors in joints and muscles. Motion sickness develops when repeated and sustained mismatches occur between the information received from the sensory receptors and the expected internal model. It is claimed that adaptation is evidence of the central nervous system’s gradual recognition that conflicting sensory inputs are being received. This leads to appropriate reductions in symptoms.

The incidence of motion sickness has been examined in diverse populations (Antuano 1989; Lawther 1988; Unger 1988). Unger 1988 found that 64.3% of 2,358 pilots undergoing flight simulator training reported at least one adverse symptom. Lawther’s (1988) study on board passenger ferries also showed similar results with 7% of 20,029 individuals reporting bouts of vomiting. A positive diagnosis of motion sickness was further established for 64% of 45 military parachutists on their first jump by Antuano 1989. However, estimates should be understood in the context of the sensory conflict hypothesis. Theoretically, all individuals may suffer from motion sickness symptoms when subject to the necessary stimulus. In this general sense, the incidence and the prevalence of the disorder is dependent on each person’s susceptibility and capacity to adapt to the stimulus as much as it is to the nature of the stimulus itself. Of equal importance is the disabling nature of the disorder when afflicted individuals are unable to perform work-related tasks, although this aspect of the disorder has been studied less.

Description of the intervention
The prevention and control of motion sickness symptoms has involved the use of pharmacological interventions, behavioural therapy and complementary medicine with varying success. Scopolamine (hyoscine), an anticholinergic, is one of the most commonly used pharmacological agents for motion sickness. Other commonly used drugs include other anticholinergics (e.g. zanifénicin), antihistamines (e.g. meclozine, flunarizine), sympathomimetics and opioids. Visualisation and biofeedback are two behavioural therapies that have been examined. Complementary medical therapies that have been used include acupuncture, acupuncture and herbal remedies.

How the intervention might work
Scopolamine is an alkaloid drug which is derived from solanaceous plants, chiefly from henbane (Hyoscyamus niger). Its pharmacological properties arise through interference with the transmission of vestibular input to the central nervous system. This acts to inhibit the vomiting impulse normally activated by motion sickness. Scopolamine can be delivered through a variety of means, including intravenous injection, ingestion of tablets or liquid formulations, or topical application with adhesive transdermal patches. The duration of treatment effectiveness varies according to the method of administration. For example, transdermal patches may be effective for up to three days, whilst tablets may need to be taken every six hours for continued efficacy. Adult doses are typically 0.3 to 0.6 mg daily, whilst smaller doses of approximately 0.006 mg/kg are administered to children. Adverse effects experienced are typical of parasympathetic system depression and include drowsiness, dilated pupils, rapid heartbeat, and dry skin, mouth and respiratory passages. Overdose of scopolamine may cause symptoms of delirium, delusions, memory disturbances, paralysis and stupor. Withdrawal symptoms have also been noted after discontinuation following prolonged use and include dizziness, nausea, headache and vomiting.

Why it is important to do this review
To date, there have been no known systematic reviews of the effectiveness of scopolamine in preventing and controlling motion sickness.

OBJECTIVES
The objective of this review was to assess the effectiveness of scopolamine versus no therapy, placebo, other drugs, behavioural and complementary therapy, or two or more of the above therapies in combination, for motion sickness in persons (both adults and children) without known vestibular, visual or central nervous system pathology. The review focused on the two broad areas of prevention and treatment.

METHODS
Criteria for considering studies for this review

Types of studies
We included all parallel-arm, randomised controlled trials (RCTs) that focused on scopolamine versus no therapy, placebo, other drugs, behavioural and complementary therapy or two or more of the above therapies in combination.

Types of participants
We focused on participants with motion sickness and no known vestibular, visual or central nervous system pathology. Studies were included regardless of the method used to induce motion sickness.
We examined treatments administered as a single-agent therapy for preventing and treating motion sickness, regardless of route. If a second active ingredient was included during administration, we only examined those studies that had a group concurrently on scopolamine alone. We compare scopolamine, where possible, to each of the following comparison therapies:

- no therapy;
- placebo;
- other drugs (anticholinergics, antihistamines, sympathomimetics, antiemetics, opioids);
- scopolamine plus another drug;
- behavioural therapies (biofeedback, visualisation);
- complementary therapies (acupressure, acupuncture, herbal remedies);
- two or more of the above therapies in combination.

**Types of outcome measures**

Studies were eligible for inclusion if they reported any of the following outcome measures.

**Primary outcomes**

Prevention of onset and treatment of clinically defined motion sickness - differences in frequency, duration and severity of symptoms.

**Secondary outcomes**

- Task ability and psychological tests (tapping speed or the Burdon Wiersma test).
- Changes in physiological parameters (heart rate, nystagmus, vagal tone, electrogastrography).
- Adverse effects (dry mouth, drowsiness, visual disturbances).

**Search methods for identification of studies**

We conducted systematic searches for randomised controlled trials. There were no language, publication year or publication status restrictions. The date of the last search was 14 April 2011, following previous searches in 2009 and 2007.

**Electronic searches**

We searched the following databases from their inception for published, unpublished and ongoing trials: the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2011); PubMed; EMBASE; CINAHL; LILACS; KoreaMed; IndMed; PakMediNet; CAB Abstracts; Web of Science; BIOSIS Previews; CNKI; ISRCTN; ClinicalTrials.gov; ICTRP and Google.

We modelled subject strategies for databases on the search strategy designed for CENTRAL. Where appropriate, we combined subject strategies with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in The Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011)). Search strategies for major databases including CENTRAL are provided in Appendix 1.

**Data collection and analysis**

We scanned reference lists of identified studies for further trials. We searched PubMed, TRIPdatabase, NLH ENT & Audiology Specialist Library and Google to retrieve existing systematic reviews possibly relevant to this systematic review, in order to search their reference lists for additional trials. We sought abstracts from conference proceedings via the Cochrane Ear, Nose and Throat Disorders Group Trials Register.

**Selection of studies**

In the original review, two review authors (AS, JW) scanned records retrieved by the initial search to exclude obviously irrelevant studies and to identify trials that met the inclusion criteria. We retrieved full-text articles and the authors reviewed these independently for the purpose of applying the inclusion criteria. In all instances, we resolved differences of opinion by discussion among the authors. In the 2009 and 2011 updates, records were retrieved, scanned and reviewed in a similar manner.

**Data extraction and management**

Two authors (AS and JW) extracted data from the studies independently using standardised forms developed for this review. Due to the length of time since publication of many of the included studies, we did not contact the authors of primary studies to provide information when missing or incomplete data were encountered. All differences were resolved by discussion among the review authors.

**Assessment of risk of bias in included studies**

We assessed study quality using an adaptation of the method outlined in Schulz 1995. Results from the study quality are presented in a descriptive manner. We assessed the following characteristics:
Adequacy of the randomisation process
A: Adequate sequence generation is reported using random number tables, computer random number generator, coin tossing or shuffling.
B: Did not specify one of the adequate reported methods in (A) but mentioned randomisation method.
C: Other methods of allocation that may not be random.

Adequacy of the allocation concealment process
Trials were awarded the following grades for allocation concealment:
A: Adequate: a randomisation method described that would not allow an investigator/participant to know or influence an intervention group before an eligible participant entered the study, such as central randomisation; serially numbered, opaque, sealed envelopes.
B: Unclear: trial states that it is ‘randomised’, but no information on the method used is reported or a method is reported that was not clearly adequate.
C: Inadequate: inadequate method of randomisation used, such as alternate medical record numbers or unsealed envelopes; or any information in the study that indicated investigators or participants could influence the intervention group.

Potential for selection bias after allocation
A: Yes: specifically reported by authors that intention-to-treat was undertaken and this was confirmed on study assessment, or not stated but evident from study assessment that intention-to-treat was undertaken.
B: Unclear: reported, but unable to confirm on study assessment, or not reported and unable to confirm by study assessment.
C: No: lack of intention-to-treat confirmed on study assessment (patients who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study or were not included because of protocol violation) regardless of whether intention-to-treat reported or not.

Completeness of follow up
Percentage of participants for whom data was complete at defined study endpoint.

Level of masking (treatment provider, patient, outcome assessor)
A: Trials which report any blinding of either outcome assessor (most likely) or treatment provider or patient (less likely).
B: Blinding not undertaken.
C: Unclear whether any blinding was undertaken.

Data synthesis
We used Review Manager 5.1 (RevMan 2011) for data analysis and quantitative data synthesis. For dichotomous data, we calculated individual and pooled statistics as risk ratio (RR) with 95% confidence intervals (95% CI). We gave consideration to the appropriateness of meta-analysis in the presence of significant clinical or statistical heterogeneity. We tested for heterogeneity using the I^2 statistic and significant heterogeneity was assumed if the I^2 was greater than 40% (i.e. more than 40% of the variability in outcome between trials could not be explained by sampling variation) (Higgins 2003). We used a fixed-effect model in the absence of statistical heterogeneity and a random-effects model if heterogeneity was likely.

RESULTS
Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.

Results of the search
In our first update in 2007, 35 studies were considered potentially relevant. Of the 35 articles assessed in full-text format, nine were excluded because of non-randomisation to treatment groups or failure to report on the method of allocation, 10 were excluded because of design (e.g. cross-over trials), one lacked an appropriate control group, one involved scopolamine only, one examined peripheral vestibular vertigo rather than motion sickness and one was awaiting translation. Therefore, 14 randomised controlled trials formed the basis of that review.
For the 2009 update of the review, the searches were repeated in April 2009. From independent scrutiny of the titles and abstracts, 14 potentially relevant articles were retrieved and excluded from the review because of study design (e.g. cross-over trials, narrative reviews), leaving us with the same number of studies as in 2007. Further details can be found in the ‘Characteristics of included studies’ table.
In 2011 we ran full searches again and retrieved 16 references. Following initial screening of titles and abstracts we considered three papers further for potential inclusion, however all were excluded (see ‘Characteristics of excluded studies’ table).

Included studies
Fourteen randomised controlled trials, with a total of 1025 participants, compared preventative transdermal scopolamine with placebo, scopolamine derivatives, scopolamine combinations, antihistamines and calcium channel antagonists. Participants were
predominantly young, healthy males, only three studies having recruited female participants (Dornhoffer 2004; Offenloch 1986; Price 1981) and three studies not specifying gender (Brand 1968; Hargreaves 1982; Tokola 1984). A large number of participants, with ages ranging from 16 to 55 years, were naval personnel on training or service exercises. Most studies specifically recruited participants with a history of motion sickness. Scopolamine was administered to participants in several ways, the most common being transdermal patches (Attias 1987; Becker 1984; How 1988; Offenloch 1986; Price 1981; van Marion 1985) and oral tablets or capsules (Brand 1968; Dornhoffer 2004; Hargreaves 1982; Laitinen 1981; Nuotto 1983; Pingree 1994; Tokola 1984). Intravenous scopolamine was tested in one study (Nuotto 1983) and an oral, water-based solution was used in another (Uijdehaage 1993).

The studies compared the efficacy of scopolamine for preventing or treating motion sickness with either placebo (Attias 1987; How 1988; Laitinen 1981; Price 1981; Tokola 1984; Uijdehaage 1993; van Marion 1985), calcium channel antagonists (Hargreaves 1982; Pingree 1994), the antihistamines meclozine (Becker 1984) and dimenhydrinate (Offenloch 1986; Price 1981), methscopolamine (Uijdehaage 1993) or a combination of scopolamine with ephedrine, cyclizine or placebo (Brand 1968; Laitinen 1981; Nuotto 1983; Tokola 1984). One study (Dornhoffer 2004) compared scopolamine to the benzodiazepine derivative, lorazepam, and the antihistamine, meclozine. No studies were found comparing scopolamine with behavioural or complementary therapies.

Motion sickness was either purposely induced or occurred due to natural circumstances. Sailing was the most common method of inducing sickness, with trip lengths ranging from seven hours to two weeks. Two studies used simulators to induce sickness and one study tested treatment effectiveness during a one-hour flight.

### Risk of bias in included studies

Results of the risk of bias assessment are provided in the ‘Characteristics of included studies’ table. The methodological quality of the trials was assessed independently by two authors and was described descriptively (AS and JW). The included studies were of varying methodological quality.

All studies were reported as randomised but only one (Laitinen 1981) described generation of the allocation sequence. Allocation was reported as being adequately concealed in three studies (Becker 1984; Nuotto 1983; Offenloch 1986) and was unclear in the remaining 11 studies. Although 12 of the studies were double-blinded, two studies (Attias 1987; Hargreaves 1982) failed to report on its masking. All studies failed to report on losses to follow up and no intention-to-treat analysis was undertaken. No attempt was made to contact authors to clarify this concern.

Study populations were generally small in size and mostly male. Most studies reported clear, though sometimes brief, inclusion and exclusion criteria.

### Effects of interventions

The results are presented in four sections reflecting the type of outcome measure identified as being of interest: prevention of sickness symptoms (nausea), prevention of vomiting, task ability and psychological tests, and adverse events. No randomised controlled trials were identified examining the effectiveness of scopolamine in the treatment of established symptoms of motion sickness.

### Primary outcomes

#### Prevention of sickness symptoms (nausea)

Five studies (Attias 1987; Laitinen 1981; Price 1981; Tokola 1984; Uijdehaage 1993) showed a superior effect of transdermal scopolamine over placebo for preventing sickness symptoms. The risk ratio (RR) was 0.48 (95% confidence interval (CI) 0.32 to 0.73) (Analysis 1.1). A further three studies (Dornhoffer 2004; How 1988; van Marion 1985) also suggested a superior effect of scopolamine over placebo for preventing or delaying motion sickness symptoms, but these could not be pooled due to the absence of data and poor or significant variations in reporting. Uijdehaage 1993 found transdermal scopolamine was superior in preventing sickness when compared to methscopolamine (RR 0.33; 95% CI 0.09 to 1.19). When compared to the antihistamine meclozine, scopolamine showed a decrease in the mean motion sickness score (motion sickness score: 89% with scopolamine versus 59% with meclozine) (Becker 1984), and delayed the onset of symptoms for longer than meclozine (mean time and percentage increase from baseline: 4.32 minutes (32.47%) with scopolamine versus 0.58 seconds (8.66%) with meclozine (Dornhoffer 2004)). Transdermal scopolamine was equivalent to other antihistamines such as promethazine (Dornhoffer 2004) and dimenhydrinate (Offenloch 1986) in preventing motion sickness. Studies comparing the effectiveness of scopolamine with cinnarizine produced mixed results. One study (Pingree 1994) found scopolamine superior to cinnarizine in preventing seasickness symptoms amongst 179 participants serving on two warships for periods of up to 60 and 40 hours, respectively. A higher prevalence of seasickness was found in the cinnarizine group (range 10% to 60%) than in the scopolamine group (range 10% to 35%). A second trial enrolling 39 participants (Hargreaves 1982) showed scopolamine to be less likely to prevent symptoms of seasickness than cinnarizine. Eighty-one percent of participants administered scopolamine (n = 21) versus 89% of those administered cinnarizine (n = 18) reported that the treatment helped either “a little” or “very much” in preventing symptoms.

When scopolamine alone or in combination with ephedrine was studied (Laitinen 1981; Tokola 1984), the meta-analysis showed no statistically significant results, although fewer participants treated with scopolamine alone reported symptoms. The pooled RR was 0.70 (95% CI 0.39 to 1.26) (Analysis 1.2). Scopolamine...
was more effective at delaying the onset of motion sickness than lorazepam which was found to hasten the onset of symptoms: mean time and percentage change from baseline: 4.32 minutes (32.47%) with scopolamine compared with -1.35 minutes (-1.65%) with lorazepam (Dornhoffer 2004).

Prevention of vomiting

Two studies (Laitinen 1981; Tokola 1984) compared the effectiveness of scopolamine with the combination of scopolamine and ephedrine. Only five cases of vomiting were reported overall. The pooled RR was 1.31 (95% CI 0.28 to 6.00) (Analysis 2.1). A third study by van Marion 1985 found no significant difference in the prevention of vomiting between those taking scopolamine and placebo (reported as a percentage of subjects: 27% taking scopolamine versus 30% taking placebo) at day one. Similar figures were also reported for days two, three and four.

Secondary outcomes

Task ability and psychological tests

Four studies (Brand 1968; Nuotto 1983; Pingree 1994; van Marion 1985) compared task ability and psychological testing. These studies could not be pooled due to the differences in outcomes. Participants administered either scopolamine or placebo during calculation and an audio-visual checking test showed no marked difference in performance (Brand 1968). This lack of effect was observed in a second study (Nuotto 1983) in which no significant memory impairment was shown for both reverse order repetition tests and paired association learning tasks in participants administered scopolamine compared with those administered placebo. There were no differences between the performance in Tapping speed, Burdon Wiersma test or Digit Symbol Test. Pingree 1994 assessed performance impairment in participants treated with either scopolamine or cinnarizine whilst serving on two separate warships. On the first ship, the two groups reported similar impairment levels of 10% to 20%. On the second ship, a higher level of performance impairment was reported by participants treated with scopolamine (up to 40%) compared with cinnarizine (less than 10%). In the last study, van Marion 1985 assessed the processing of information by using the Burdon Wiersma test which, performed before application of the patch and 24 hours thereafter, revealed no difference between the scopolamine and placebo group. At the second testing, all participants performed better, probably because of the known learning effect with information and task-related activities.

Adverse events

Drowsiness

Two studies (Laitinen 1981; Uijdehaage 1993) compared scopolamine with placebo for the experience of drowsiness. With 60 individuals participating, no significant difference between the two treatments was noted despite a trend toward greater drowsiness amongst participants using scopolamine (pooled RR 1.42; 95% CI 0.79 to 2.56) (Analysis 3.1). A further two studies (Price 1981; van Marion 1985) found no statistically significant difference in the prevalence of drowsiness amongst its participants. Drowsiness was also measured in two studies that compared scopolamine with cinnarizine. The first study (Hargreaves 1982) found scopolamine was more likely to induce drowsiness (3/21 participants) compared to those in the cinnarizine group (0/18 participants). The second study (Pingree 1994) found no statistically significant differences between the two treatment groups. However, the study (Pingree 1994) reported a higher prevalence of drowsiness amongst participants treated with either scopolamine or placebo, although the data could not be pooled due to poor reporting. One study (Uijdehaage 1993) comparing scopolamine to methscopolamine found no significant difference in the prevalence of drowsiness amongst its participants.

Blurred vision

Two studies found no significant difference when comparing the incidence of blurred vision with scopolamine and placebo (RR 2.73; 95% CI 0.89 to 8.37; P = 0.08) (Analysis 4.1) (Uijdehaage 1993; van Marion 1985). A third study by Price 1981 reported no differences in the participants’ vision when treated with either scopolamine or placebo (results not presented graphically; P value not reported). When comparing the symptoms of blurred vision in those taking scopolamine versus cinnarizine, Pingree 1994 reported a significantly greater prevalence of visual disturbances amongst participants treated with scopolamine than those treated with cinnarizine.

Dry mouth

Three studies (Price 1981; Uijdehaage 1993; van Marion 1985) found that the symptom of dry mouth was apparent in those treated with scopolamine rather than placebo. In the first study (Uijdehaage 1993), 7/20 (35%) participants reported dry mouth symptoms compared to 1/20 (5%) in the placebo arm. When treated with methscopolamine, the same study found a greater prevalence of dry mouth symptoms amongst participants treated with scopolamine (35%) than methscopolamine (10%). In the study by van Marion 1985, the prevalence of dry mouth on days three and four was significantly higher amongst participants administered scopolamine compared to placebo (reported
as a percentage of subjects: 34% taking scopolamine versus 7% taking placebo at day three, \( P < 0.01 \); and 31% taking scopolamine versus 9% taking placebo at day four, \( P < 0.05 \). However, there was no difference between groups experiencing dry mouth at days one and two (reported as a percentage of subjects: 26% taking scopolamine versus 23% taking placebo at day one and 36% taking scopolamine versus 25% taking placebo at day two). This may have been because the symptom of dry mouth may have accompanied nausea and motion sickness experienced early in the voyage.

A study (Pingree 1994) comparing scopolamine with cinnarizine reported a significantly greater prevalence of dry mouth in those treated with scopolamine rather than cinnarizine. Scopolamine was also more likely to cause symptoms of dry mouth for those treated with dimenhydrinate (Offenloch 1986). Five (50%) participants treated with scopolamine reported mild to moderate dry mouth symptoms, whereas no such symptoms were reported by participants treated with dimenhydrinate.

**Dizziness**

Two studies (Uijdehaage 1993; van Marion 1985) compared scopolamine with other treatments for the adverse symptom of dizziness. In the first study, van Marion 1985 found no difference with the onset of dizziness between scopolamine and the placebo group (reported as a percentage of subjects: 15% taking scopolamine versus 26% taking placebo at day one and 27% taking scopolamine versus 22% taking placebo at day two). In the second study (Uijdehaage 1993), 10% (n = 20) of scopolamine-treated participants reported dizziness compared with no participants treated with either placebo or methscopolamine alone.

**DISCUSSION**

There is evidence to support the use of scopolamine versus placebo in the prevention of sickness symptoms such as nausea and vomiting. Scopolamine in conjunction with ephedrine was not significantly different, although fewer participants treated with scopolamine alone reported symptoms. Many of the other trials using other agents were far less than conclusive.

Trials using antihistamines as a comparator showed mixed results for decreasing motion sickness with one study highlighting scopolamine’s superiority (Becker 1984) and the other claiming equal efficacy (Offenloch 1986). Both studies included a small number of participants, indicating the likelihood of an underpowered study. Neither study design nor outcome definitions could have explained this heterogeneity. The variety of histamine antagonists used was the most plausible explanation, but could not be confirmed given the different types of antihistamines used within the studies and the lack of consistent outcome reporting by type of antihistamine exposure.

Two of the studies that used cinnarizine as comparator could not be pooled thus providing only a descriptive analysis of their effectiveness. Cinnarizine was far less effective than scopolamine but, in an alternative trial by Hargreaves, the two drugs were reported as being “statistically indistinguishable” in preventing nausea and vomiting symptoms. The reported differences could not be explained, but perhaps the aggressive motion (Pingree 1994) interacted with the drug action to result in the superior efficacy of scopolamine with an associated comparative reduction in side effects as motion severity increased.

Adverse effects in the form of level of drowsiness, blurred vision, dry mouth and dizziness were reported amongst the studies. A trend towards increased drowsiness was noted when scopolamine was compared to placebo, scopolamine derivatives and calcium channel antagonists. The dry mouth and visual disturbances were seen as being well-documented peripheral side effects of anticholinergic drugs rather than a manifestation of motion sickness. Conversely, participants might have had difficulty in distinguishing between the symptoms observed during motion sickness and those that were included in the category of adverse effects. In the poorly defined nauseogenic conditions that defined some studies (Hargreaves 1982), cinnarizine had less profound side effects and was better tolerated than scopolamine.

It is important to note that the method of scopolamine delivery varied across the studies. There were three possible delivery modes tested: oral (tablets or liquid), intravenous and transdermal, with half of the studies using transdermal scopolamine systems and the remaining testing oral preparations with one testing both oral and intravenous routes. The transdermal patch was most likely used to minimise the relatively high incidence of adverse effects seen with other routes of administration. More importantly, the main pharmokinetic difference between these delivery modes is the time taken for plasma concentrations to reach therapeutic levels with intravenous and oral routes taking one to two hours to take effect for a period of six hours while the transdermal routes take approximately eight hours to become therapeutically effective for over 72 hours. Additionally, the dosage of oral scopolamine administered to subjects ranged from 0.1 to 0.9 mg which would mean that plasma concentration levels of scopolamine would have differed between these studies.

Although scopolamine was seen to be effective for the prevention of sickness symptoms, methodological quality issues and small sample sizes may have limited the validity of these findings. The largest study included 179 participants and six of the 12 studies included 50 participants or fewer. No studies investigated the effectiveness or tolerance of scopolamine in children, and only two studies reported recruiting female participants. In the studies where scopolamine was found to be no more effective than a comparator (e.g. antihistamines), lack of sufficient power may have resulted in an erroneous conclusion. Furthermore, the quality of the trials varied. There were many opportunities for systematic bias as only a
minority reported on an appropriate method of randomisation or on concealment of allocation, although incomplete reporting did not necessarily mean that the effectiveness of scopolamine was in doubt. Despite the potential biases that would most likely work against the intervention arm, the overall findings were that scopolamine was effective as a means of preventing motion sickness.

It appears that research into the effectiveness of scopolamine for treating or preventing motion sickness has declined since its peak during the 1980s. Only three of the included studies were conducted in the past 15 years. Similarly, only five of the 20 excluded studies were conducted in this time period. Examining the included studies in chronological order did not reveal any consistent pattern of dosage, method or comparators, and the general methodological quality did not improve over time.

**Authors’ Conclusions**

**Implications for practice**

The use of scopolamine versus placebo in preventing motion sickness has been shown to be effective. No conclusions or recommendations can be made on the comparative effectiveness of scopolamine and other agents such as antihistamines and calcium channel antagonists. In addition, no randomised controlled trials were identified that examined the effectiveness of scopolamine in the treatment of established symptoms of motion sickness.

**Implications for research**

The lack of high quality evidence showing the effectiveness and safety of scopolamine for preventing or treating motion sickness in women and children indicates a gap that should be a priority for future research studies. Well-designed randomised controlled trials with sufficient power are also needed to test the effectiveness of scopolamine compared to other pharmaceutical therapies, as well as behavioural and complementary therapies. The synthesis of future trials would be assisted if standardised outcome, motion condition and treatment regimes and/or dosages were used. All trials should also include a measure of adverse outcomes so that more evidence is available to compare the safety of scopolamine with other treatments.

**Acknowledgements**

We wish to thank Vivienne Bernath and Elmer Villanueva for their authorship contributions to earlier versions of this review. We also wish to thank Gemma Sandberg for her assistance with updating the search and running the search strategy in multiple databases. The clinical question arose from a project funded by the General Practice Evaluation Program (Del Mar 2001).

**References**

- Attias 1987 *(published data only)*

- Becker 1984 *(published data only)*

- Brand 1968 *(published data only)*

- Dornhoffer 2004 *(published data only)*

- Hargreaves 1982 *(published data only)*

- How 1988 *(published data only)*

- Laitinen 1981 *(published data only)*

- Nuotto 1983 *(published data only)*

Scopolamine (hyoscine) for preventing and treating motion sickness (Review)

Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
References to studies excluded from this review

Aizikov 1985 [published data only]

Bar 2009 [published data only]

Bodo 1982 [published data only]

Brand 1967 [published data only]

References to studies included in this review

Brand 1969 [published data only]

Cipriani 1987 [published data only]

Cirillo 1986 [published data only]

Estrada 2007 [published data only]

Galle 1988 [published data only]

Glaznikov 1992 [published data only]

Gordon 2001 [published data only]

Gowans 2000 [published data only]

Hordinsky 1982 [published data only]

Howland 2006 [published data only]

Ilyina 1986 [published data only]

Klocker 2001 [published data only]
Klocker N, Hanschke W, Toussaint S, Vere T. Scopolamine nasal spray in motion sickness: a randomised, controlled,

Nobel 2010 [published data only]

Norfleet 1992 [published data only]

Pyykko 1984 [published data only]


Sabato 1987 [published data only]

Simmons 2010 [published data only]

Vigliano 1986 [published data only]

Vigliano 1987 [published data only]

Wang 1990 [published data only]

Wolf 1987 [published data only]

Additional references

Antuano 1989

Del Mar 2001

Handbook 2011

Higgins 2003

Lawther 1988

Oman 1990

Reason 1970

Reason 1975

RevMan 2011

Schultz 1995

Ungs 1988
Yardley 1992


* Indicates the major publication for the study
### CHARACTERISTICS OF STUDIES

#### Characteristics of included studies  *(ordered by study ID)*

**Attias 1987**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised controlled trial comparing adverse effects and efficacy of transdermal scopolamine with placebo for preventing seasickness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>38 male volunteers aged 20 to 25 years</td>
</tr>
<tr>
<td>Interventions</td>
<td>Transdermal scopolamine or identical placebo patches applied prior to a 3-day cruise. No dosage information was provided</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Subjective ratings of seasickness and adverse effects of treatment</td>
</tr>
<tr>
<td>Notes</td>
<td>All participants were disallowed drugs or alcohol during the study. Schulz rating: randomisation B; allocation concealment B; selection bias B; blinding C</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

**Becker 1984**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised, parallel-arm trial comparing adverse effects and efficacy of transdermal scopolamine with oral meclozine for preventing motion sickness in an artificial sea voyage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>46 healthy, male marines aged 18 to 27 years. 19 displayed susceptibility to motion sickness in a pre-experiment</td>
</tr>
<tr>
<td>Interventions</td>
<td>Transdermal scopolamine or oral meclozine tablets taken prior to an artificial sea voyage</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Motion sickness score. Digestibility of treatment.</td>
</tr>
<tr>
<td>Notes</td>
<td>Schulz rating: randomisation B; allocation concealment A; selection bias B; blinding A</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>
### Brand 1968

<table>
<thead>
<tr>
<th><strong>Methods</strong></th>
<th>Randomised, parallel-arm, controlled trial comparing psycho-physiological effects of scopolamine, cyclizine and placebo in the prevention of motion sickness</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Participants</strong></td>
<td>120 sailors. No information was provided on age or gender.</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>Oral doses of placebo, scopolamine (0.1 mg, 0.42 mg, 0.7 mg) or cyclizine (15 mg or 100 mg) administered prior to various tests</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Objective measurements of salivation, pulse rate, power of accommodation and mental performance</td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td>Schulz rating: randomisation B; allocation concealment B; selection bias B; blinding A</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th><strong>Bias</strong></th>
<th><strong>Authors’ judgement</strong></th>
<th><strong>Support for judgement</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

### Dornhoffer 2004

<table>
<thead>
<tr>
<th><strong>Methods</strong></th>
<th>Randomised, controlled trial comparing the efficacy of scopolamine, lorazepam, meclizine, promethazine and placebo for protecting against motion sickness</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Participants</strong></td>
<td>75 healthy male and female volunteers aged 18 to 44 years, with no neurologic or psychiatric disorders and no known allergies or previous adverse drug reactions</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>Scopolamine (0.4 mg), lorazepam (1 mg), meclizine (25 mg), promethazine (25 mg) or placebo administered 45 minutes prior to blindfolding and chair rotation. Subjects were required to perform head movements during rotation</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Measurement of rotation duration until subject requested termination due to motion sickness symptoms, could no longer perform head movements or maximum rotational velocity had been tolerated</td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td>Subjects were determined to be free of all medication and alcoholic substances 72 hours prior and at time of testing. Schulz rating: randomisation B; allocation concealment B; selection bias B; blinding A</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th><strong>Bias</strong></th>
<th><strong>Authors’ judgement</strong></th>
<th><strong>Support for judgement</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>D - Not used</td>
</tr>
</tbody>
</table>
### Hargreaves 1982

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised, parallel-arm trial comparing the efficacy of scopolamine with cinnarizine for preventing seasickness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>39 volunteers from the Ocean Youth Club with known susceptibility to seasickness. No information was provided on gender</td>
</tr>
<tr>
<td>Interventions</td>
<td>Either two 15 mg cinnarizine tablets or one 0.3 mg hyoscine tablet taken 1 to 2 hours prior to sailing and thereafter every 6 to 8 hours</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Subjective reporting of efficacy of treatment (not at all, a little or very much) and drowsiness</td>
</tr>
<tr>
<td>Notes</td>
<td>Schulz rating: randomisation B; allocation concealment B; selection bias B; blinding C</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

### How 1988

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised, controlled trial comparing efficacy of transdermal scopolamine with placebo for preventing seasickness in both experienced and inexperienced sailors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>122 officers and naval men who were either experienced (&lt; 1 year in navy, n = 59) or inexperienced (&lt; 1 year in navy, n = 63). Participant ages ranged from 19 to 45 years</td>
</tr>
<tr>
<td>Interventions</td>
<td>Transdermal Scopaderm TTS (1.5 mg scopolamine) or identical placebo patches applied 4 hours prior to sailing and then replaced every third day during sea voyage</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Subjective analogue scale measurement of degree of seasickness experienced during previous 24 hours at 8am every day</td>
</tr>
<tr>
<td>Notes</td>
<td>No restrictions of food, water or other medications were imposed. Schulz rating: randomisation B; allocation concealment B; selection bias B; blinding A</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>
Laitinen 1981

Methods
Randomised controlled trial comparing adverse effects and efficacy of scopolamine, scopolamine + ephedrine and placebo for preventing seasickness

Participants
30 male naval cadets aged 20 to 24 years. Participants with heart disease, hypertension, central nervous system disease, untreated angle closure glaucoma or prostate hypertrophy were excluded

Interventions
Gelatinous capsules of either scopolamine hydrobromide (0.3 mg), scopolamine hydrobromide + ephedrine hydrochloride (25 mg), or placebo administered 3 times a day at 5 to 6-hour intervals over 5 days for prophylactic treatment of seasickness during crossing of Baltic and North Seas

Outcomes
Subjective grading of efficacy of treatment and side effects

Notes
No alcohol or central nervous depressants were allowed during the study. Participants were provided with 3 suppositories of 100 mg pyridoxine hydrochloride as supplementary medication if required

Schulz rating: randomisation A; allocation concealment B; selection bias B; blinding A

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

Nuotto 1983

Methods
3 placebo-controlled randomised trials comparing the psycho-physiological effects of scopolamine and ephedrine in the prevention of motion sickness

Participants
58 young, healthy male volunteers

Interventions
Study 1: intravenous scopolamine (7.6 mg/kg) or intravenous placebo (0.9% NaCl)
Studies 2 and 3: oral doses of scopolamine hydrobromide (0.3 mg, 0.9 mg) ephedrine (25 mg), combined scopolamine hydrobromide and ephedrine (0.3 mg + 25 mg; 0.9 mg + 25 mg) or placebo (lactose)

Outcomes
A. Objective measurements of psycho-physiological effects of treatment measured by the following tests: co-ordination, reactive skills, tapping speed, hand co-operation, speed anticipation, body sway, flicker fusion, eso- and exophoria, nystagmus, near point of vision and pupil diameter, memory and learning tasks, digit symbol substitution, Burdon Wiersma, blood pressure and heart rate
B. Subjective assessments of current state using visual analogue rating scales

Notes
Schulz rating: randomisation B; allocation concealment A; selection bias B; blinding A

Risk of bias
**Nuotto 1983** *(Continued)*

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>

**Offenloch 1986**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised, parallel-arm trial comparing transdermal scopolamine with oral antiemetic dimenhydrinate for the prevention of motion sickness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>20 volunteers (15 male, 5 female) aged 20 to 47 years with proven motion sickness</td>
</tr>
<tr>
<td>Interventions</td>
<td>Transdermal scopolamine or oral dimenhydrinate taken prior to a 1-hour flight</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Subjective assessment of therapeutic effectiveness. Incidence of adverse effects (tiredness, dry mouth, mouth dryness)</td>
</tr>
<tr>
<td>Notes</td>
<td>Schulz rating: randomisation B; allocation concealment A; selection bias B; blinding A</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>

**Pingree 1994**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised, double-blind trial comparing scopolamine with cinnarizine in the prevention and treatment of seasickness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>179 healthy male volunteer personnel with a history of seasickness serving on 2 warships</td>
</tr>
<tr>
<td>Interventions</td>
<td>Prophylactic treatment of seasickness with gelatin capsules containing either scopolamine (or cinnarizine). Treatment was dispensed 4 hours prior to nauseogenic ship motion and continued at 6-hour intervals. Dosage information was not provided</td>
</tr>
<tr>
<td>Outcomes</td>
<td>6-hour intervals of subjective scores for a range of symptoms including: seasickness, headache, stomach awareness, drowsiness, dry mouth, visual disturbance, performance impairment and number of vomiting events</td>
</tr>
<tr>
<td>Notes</td>
<td>Schulz rating: randomisation B; allocation concealment B; selection bias B; blinding A</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Price 1981

<table>
<thead>
<tr>
<th>Allocation concealment (selection bias)</th>
<th>Unclear risk</th>
<th>B - Unclear</th>
</tr>
</thead>
</table>

#### Methods
Four randomised, double-blind, placebo-controlled clinical trials in the prevention and treatment of motion sickness

#### Participants
161 healthy men and women with a history of motion sickness. Participants ages ranged from 16 to 55 years

#### Interventions
Transdermal scopolamine (0.5 mg) delivered constantly over 72 hours), placebo or oral dimenhydrinate taken either before or during a 7 to 8-hour cruise

#### Outcomes
Subjective reporting of symptoms every 1 or 2 hours during exposure to motion (scale of 0 to 6) and occurrence of dry mouth, drowsiness and blurred vision

#### Notes
Subjects who requested extra medication received supplemental medication of 200 mcg of intramuscular scopolamine hydrobromide

Schulz rating: randomisation B; allocation concealment B; selection bias B; blinding A

### Tokola 1984

<table>
<thead>
<tr>
<th>Allocation concealment (selection bias)</th>
<th>Unclear risk</th>
<th>B - Unclear</th>
</tr>
</thead>
</table>

#### Methods
Randomised, placebo-controlled, double-blind trials comparing efficacy of scopolamine alone or with ephedrine for prevention of seasickness

#### Participants
28 healthy naval volunteers

#### Interventions
Identical capsules of either scopolamine hydrobromide (0.3 mg), scopolamine hydrobromide (0.3 mg) + ephedrine hydrochloride (0.25 mg), or placebo administered 3 hours prior to sailing exercise (of 24-hour duration) and then every 6 hours

#### Outcomes
Subjective rating of seasickness and side effects

#### Notes
Participants were provided with 5 suppositories of pyridoxine hydrochloride 100 mg to be taken if necessary. A second trial is reported in this study. This trial is excluded

Schulz rating: randomisation B; allocation concealment B; selection bias B; blinding A
Uijdehaage 1993

Methods
Randomised controlled trial comparing scopolamine with methscopolamine and placebo for physiological parameter measurements and prevention of motion sickness symptoms.

Participants
60 male college students (mean age 19.7 years) who were susceptible to vection-induced motion sickness. Individuals with a history of neurological, cardiovascular or gastrointestinal disorders were not eligible.

Interventions
Solution of either scopolamine (0.6 mg), meth-scopolamine (2.5 mg) or placebo solution in 100 ml of water taken approximately 1 hour prior to vection-induced motion sickness.

Outcomes
Physiological measurements taken immediately after ingestion of treatment, after 1 hour and whilst participant is seated in drum both whilst stationary and in rotation. Subjective motion sickness scores taken every 2 minutes whilst in motion.

Notes
Subjects were requested to not use any medication, alcohol or drugs 24 hours before testing, not to drink caffeine-containing beverages 12 hours prior and to refrain from smoking, heavy exercise and eating 4 hours prior to testing.

Schulz rating: randomisation B; allocation concealment B; selection bias B; blinding A

van Marion 1985

Methods
Randomised controlled trial comparing the protective effect of transdermal scopolamine with transdermal placebo against motion sickness during a 7-day sea voyage.

Participants
49 health sailors aged 17 to 45 years with a previous history of motion sickness.

Interventions
Transdermal scopolamine (developed to release 0.5 mg constantly over 72 hours) or transdermal placebo applied 4 hours prior to departure on a 7-day sea voyage. Patches were removed after 72 hours.

Outcomes
Subjective record of motion sickness symptoms (cold sweating, pallor, nausea and vomiting), drowsiness and ability to perform tasks on a visual analogue scale on days 1, 2, 3, 4 and 6. Subjective reporting of side effects. Objective physiological measurements recorded on days 1, 4 and 6. Performance on an information processing task the day prior to departure and on day 1.
No restraints in washing or bathing were imposed. Subjects received 50 mg cyclizine tablets as supplemental medication on request.

Schulz rating: randomisation B; allocation concealment B; selection bias B; blinding A

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

### Characteristics of excluded studies  
[ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
</table>
| Aizikov 1985   | ALLOCATION  
No mention of how subjects were assigned to treatment conditions |
| Bar 2009       | ALLOCATION  
No control group present                                  |
| Bodo 1982      | ALLOCATION  
Not randomised                                                |
| Brand 1967     | ALLOCATION  
Cross-over design was used                                    |
| Brand 1969     | ALLOCATION  
Cross-over design was used                                    |
| Cipriani 1987  | ALLOCATION  
Randomised  
PARTICIPANTS  
Included patients with peripheral vestibular vertigo, not motion sickness |
| Cirillo 1986   | ALLOCATION  
Not randomised                                                |
| Estrada 2007   | ALLOCATION  
Cross-over design was used                                    |
| Galle 1988     | ALLOCATION  
No mention of how subjects were assigned to treatment conditions |
<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glaznikov 1992</td>
<td>Allocation</td>
<td>No mention of how subjects were assigned to treatment conditions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Included participants with lowered vestibule-vegetative equilibrium</td>
</tr>
<tr>
<td>Gordon 2001</td>
<td>Allocation</td>
<td>Cross-over design was used</td>
</tr>
<tr>
<td>Gowans 2000</td>
<td>Allocation</td>
<td>Cross-over design was used</td>
</tr>
<tr>
<td>Hordinsky 1982</td>
<td>Allocation</td>
<td>Cross-over design was used</td>
</tr>
<tr>
<td>Howland 2006</td>
<td>Allocation</td>
<td>Cross-over design was used</td>
</tr>
<tr>
<td>Ilyina 1986</td>
<td>Allocation</td>
<td>No mention of how subjects were assigned to treatment conditions</td>
</tr>
<tr>
<td>Klocker 2001</td>
<td>Allocation</td>
<td>Cross-over design was used</td>
</tr>
<tr>
<td>Nobel 2010</td>
<td>Outcomes</td>
<td>Did not assess motion sickness outcomes</td>
</tr>
<tr>
<td>Norfleet 1992</td>
<td>Allocation</td>
<td>Cross-over design was used</td>
</tr>
<tr>
<td>Pyyko 1984</td>
<td>Allocation</td>
<td>Cross-over design was used</td>
</tr>
<tr>
<td>Sabato 1987</td>
<td>Allocation</td>
<td>No control group present</td>
</tr>
<tr>
<td>Simmons 2010</td>
<td>Allocation</td>
<td>Cross-over design was used</td>
</tr>
<tr>
<td>Vigliano 1986</td>
<td>Allocation</td>
<td>No mention of how subjects were assigned to treatment conditions</td>
</tr>
<tr>
<td>Vigliano 1987</td>
<td>Allocation</td>
<td>No mention of how subjects were assigned to treatment conditions</td>
</tr>
<tr>
<td>Wang 1990</td>
<td>Allocation</td>
<td>No mention of how subjects were assigned to treatment conditions</td>
</tr>
</tbody>
</table>
(Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wolf 1987</td>
<td>Not randomised</td>
</tr>
</tbody>
</table>

## Data and Analyses

### Comparison 1. Prevention of sickness symptoms (nausea)

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Scopolamine vs placebo</td>
<td>5</td>
<td>165</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.48 [0.32, 0.73]</td>
</tr>
<tr>
<td>2 Scopolamine vs scopolamine + ephedrine</td>
<td>2</td>
<td>40</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.70 [0.39, 1.26]</td>
</tr>
</tbody>
</table>

### Comparison 2. Prevention of vomiting

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Scopolamine vs scopolamine + ephedrine</td>
<td>2</td>
<td>40</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>1.31 [0.28, 6.00]</td>
</tr>
</tbody>
</table>

### Comparison 3. Adverse event: drowsiness

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Scopolamine vs placebo</td>
<td>2</td>
<td>60</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>1.42 [0.79, 2.56]</td>
</tr>
</tbody>
</table>

### Comparison 4. Adverse events: blurred vision

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Scopolamine vs placebo</td>
<td>2</td>
<td>89</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>2.73 [0.89, 8.37]</td>
</tr>
</tbody>
</table>
## Analysis 1.1. Comparison 1 Prevention of sickness symptoms (nausea), Outcome 1 Scopolamine vs placebo.

**Review:** Scopolamine (hyoscine) for preventing and treating motion sickness

**Comparison:** 1 Prevention of sickness symptoms (nausea)

**Outcome:** 1 Scopolamine vs placebo

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Scopolamine</th>
<th>Placebo</th>
<th>Risk Ratio M-H Random 95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H Random 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>n/N</td>
<td>n/N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attias 1987</td>
<td>4/10</td>
<td>5/10</td>
<td>17.4 % 0.80 [0.30, 2.13]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laitinen 1981</td>
<td>4/23</td>
<td>10/24</td>
<td>16.4 % 0.42 [0.15, 1.14]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Price 1981</td>
<td>5/10</td>
<td>10/10</td>
<td>45.7 % 0.52 [0.29, 0.96]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tokola 1984</td>
<td>3/21</td>
<td>9/17</td>
<td>12.9 % 0.27 [0.09, 0.84]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uijdehaage 1993</td>
<td>2/20</td>
<td>6/20</td>
<td>7.7 % 0.33 [0.08, 1.46]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>84</strong></td>
<td><strong>81</strong></td>
<td><strong>100.0 % 0.48 [0.32, 0.73]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 18 (Scopolamine), 40 (Placebo)

Heterogeneity: Tau² = 0.0, Chi² = 2.57, df = 4 (P = 0.63), I² = 0.0%

Test for overall effect: Z = 3.50 (P = 0.00046)

Test for subgroup differences: Not applicable
### Analysis 1.2. Comparison 1 Prevention of sickness symptoms (nausea), Outcome 2 Scopolamine vs scopolamine + ephedrine.

Review: Scopolamine (hyoscine) for preventing and treating motion sickness

Comparison: 1 Prevention of sickness symptoms (nausea)

Outcome: 2 Scopolamine vs scopolamine + ephedrine

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Scopolamine</th>
<th>Scopolamine + ephedrine</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>n/N</td>
<td>n/N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laitinen 1981</td>
<td>4/10</td>
<td>7/10</td>
<td>0.57 [0.24, 1.35]</td>
<td>46.4%</td>
<td></td>
</tr>
<tr>
<td>Tokola 1984</td>
<td>5/10</td>
<td>6/10</td>
<td>0.83 [0.37, 1.85]</td>
<td>53.6%</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>20</td>
<td>20</td>
<td>0.70 [0.39, 1.26]</td>
<td>100.0%</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.0; Chi² = 0.40, df = 1 (P = 0.53); I² = 0.0%

Test for overall effect: Z = 1.19 (P = 0.23)

Test for subgroup differences: Not applicable

### Analysis 2.1. Comparison 2 Prevention of vomiting, Outcome 1 Scopolamine vs scopolamine + ephedrine.

Review: Scopolamine (hyoscine) for preventing and treating motion sickness

Comparison: 2 Prevention of vomiting

Outcome: 1 Scopolamine vs scopolamine + ephedrine

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Scopolamine</th>
<th>Scopolamine + ephedrine</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>n/N</td>
<td>n/N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laitinen 1981</td>
<td>2/10</td>
<td>2/10</td>
<td>1.00 [0.17, 5.77]</td>
<td>75.6%</td>
<td></td>
</tr>
<tr>
<td>Tokola 1984</td>
<td>1/10</td>
<td>0/10</td>
<td>3.00 [0.14, 65.90]</td>
<td>24.4%</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>20</td>
<td>20</td>
<td>1.31 [0.28, 6.00]</td>
<td>100.0%</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.0; Chi² = 0.38, df = 1 (P = 0.54); I² = 0.0%

Test for overall effect: Z = 0.34 (P = 0.73)

Test for subgroup differences: Not applicable

---

*Scopolamine (hyoscine) for preventing and treating motion sickness (Review)*

Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 3.1. Comparison 3 Adverse event: drowsiness, Outcome 1 Scopolamine vs placebo.

**Review:** Scopolamine (hyoscine) for preventing and treating motion sickness

**Comparison:** 3 Adverse event: drowsiness

**Outcome:** 1 Scopolamine vs placebo

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Scopolamine</th>
<th>Placebo</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laitinen 1981</td>
<td>9/10</td>
<td>5/10</td>
<td>6.00% 1.80 [0.94, 3.46]</td>
<td>1.80</td>
</tr>
<tr>
<td>Uijdehaage 1993</td>
<td>7/20</td>
<td>7/20</td>
<td>4.00% 1.00 [0.43, 2.33]</td>
<td>1.00</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>30</strong></td>
<td><strong>30</strong></td>
<td><strong>100.0% 1.42 [0.79, 2.56]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 16 (Scopolamine), 12 (Placebo).

Heterogeneity: $\tau^2 = 0.04$; $\chi^2 = 1.26$, df = 1 ($P = 0.26$); $I^2 = 20$

Test for overall effect: $Z = 1.18$ ($P = 0.24$)

Test for subgroup differences: Not applicable

### Analysis 4.1. Comparison 4 Adverse events: blurred vision, Outcome 1 Scopolamine vs placebo.

**Review:** Scopolamine (hyoscine) for preventing and treating motion sickness

**Comparison:** 4 Adverse events: blurred vision

**Outcome:** 1 Scopolamine vs placebo

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Control</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uijdehaage 1993</td>
<td>3/20</td>
<td>0/20</td>
<td>13.6% 7.00 [0.38, 127.32]</td>
<td>7.00</td>
</tr>
<tr>
<td>van Marion 1985</td>
<td>7/26</td>
<td>3/23</td>
<td>86.4% 2.06 [0.60, 7.07]</td>
<td>2.06</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>46</strong></td>
<td><strong>43</strong></td>
<td><strong>100.0% 2.73 [0.89, 8.37]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 10 (Treatment), 3 (Control).

Heterogeneity: $\chi^2 = 0.60$, df = 1 ($P = 0.44$); $I^2 = 0$

Test for overall effect: $Z = 1.76$ ($P = 0.078$)

Test for subgroup differences: Not applicable
A P P E N D I C E S

Appendix 1. Search strategies

<table>
<thead>
<tr>
<th>CENTRAL</th>
<th>PubMed</th>
<th>EMBASE (Ovid)</th>
<th>CINAHL (EBSCO)</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1 MOTION SICKNESS explode all trees (MeSH)</td>
<td>#1 “Motion Sickness”[Mesh]</td>
<td>1 Motion Sickness/</td>
<td>S1 (MH “Motion Sickness”)</td>
</tr>
<tr>
<td>#2 car near sick* or sea near sick* or air near sick* or travel near sick* or space near sick*</td>
<td>#2((car [tiab] OR sea [tiab] OR motion [tiab] OR air [tiab] OR travel [tiab] OR space [tiab]) AND sick* [tiab])</td>
<td>2 (car or sea or motion or air or travel or space) and sick*).tw.</td>
<td>S2 TX car or sea or motion or air or travel or space</td>
</tr>
<tr>
<td>#3 carsick* OR airsick* OR seasick* OR motionsick* OR travelsick* OR spacesick*</td>
<td>#3 carsick* OR airsick* OR seasick* OR motionsick* OR travelsick* OR spacesick*</td>
<td>3 (carsick* or airsick* or seasick* or motionsick* or travelsick* or spacesick*).tw.</td>
<td>S3 TX sick*</td>
</tr>
<tr>
<td>#4 kinetosis</td>
<td>#4 kinetosis</td>
<td>4 kinetosis.tw.</td>
<td>S4 S2 and S3</td>
</tr>
<tr>
<td>#5 #1 OR #2 OR #3 OR #4</td>
<td>#5 #1 OR #2 OR #3 OR #4</td>
<td>5 4 or 1 or 3 or 2</td>
<td>S5 TX kinetosis</td>
</tr>
<tr>
<td>#6 SCOPOLAMINE explode all trees (MeSH)</td>
<td>#6 “Scopolamine”[Mesh]</td>
<td>6 Scopolamine/</td>
<td>S6 S1 or S4 or S5</td>
</tr>
<tr>
<td>#7 atrochin OR atroquin OR atroscine OR beldavrin OR buscopan OR epypoxiprine OR euscopol OR hydroscine OR hyocine OR hyosceline OR Hyoscine OR hyoscyne OR hyosol OR hyso OR isoscipol OR kwells OR methscopolamine OR osine OR pamine OR scoburen OR scop OR scopace OR scopamia</td>
<td>#7 atrochin [tiab] OR atroquin [tiab] OR atroscine [tiab] OR beldavrin [tiab] OR buscopan [tiab] OR euscopol [tiab] OR epypoxiprine [tiab] OR hydroscine [tiab] OR hyocine [tiab] OR hyosceline [tiab] OR hyoscyne [tiab] OR hyosol [tiab] OR hyso [tiab] OR isoscipol [tiab] OR kwells [tiab] OR methscopolamine [tiab] OR osine [tiab] OR pamine [tiab] OR scoburen [tiab] OR scop [tiab] OR scopace [tiab] OR scopamia [tiab] OR scop</td>
<td>7 (atrochin or atroquin or atroscine or beldavrin or buscopan or epypoxiprine or euscopol or hydroscine or hyocine or hyosceline or hyoscyne or hyosol or hyso or isoscipol or kwells or methscopolamine or osine or pamine or scoburen or scop or scopace or scopamia or scop</td>
<td>S7 (MH “Scopolamine”)</td>
</tr>
<tr>
<td>#8 scopine OR scopoderm OR scopolamin OR scopolamin OR scopolaminhydrobromid OR scopolaminium OR scopolammonium OR scapos OR sereen OR skopolamin OR traxamine OR trancal OR triptone OR tropic NEXT acid OR vorigeno</td>
<td>#8 scopine OR scopoderm OR scopolamin OR scopolamin OR scopolaminhydrobromid OR scopolaminium OR scopolammonium OR scapos OR sereen OR skopolamin OR traxamine OR trancal OR triptone OR tropic NEXT acid OR vorigeno</td>
<td>8 (transderm or trancal or triptone or (tropic adj acid) or vorigeno).tw.</td>
<td>S8 TX atrochin or atroquin or atroscine or beldavrin or buscopan or epypoxiprine or euscopol or hydroscine or hyocine or hyosceline or hyoscyne or hyosol or hyso or isoscipol or kwells or methscopolamine or osine or pamine or scoburen or scop or scopace or scopamia or scopine or scopoderm or scopolamin or scopolaminium or scopolaminhydrobromid or scopolaminium or scopolammonium or scapos or sereen or skopolamin or traxamine or trancal</td>
</tr>
<tr>
<td>#9 #6 or #7 or #8</td>
<td>#9 #5 OR #6 OR #7</td>
<td>9 8 or 6 or 7</td>
<td>S10 S7 or S8 or S9</td>
</tr>
<tr>
<td>#10 #5 and #9</td>
<td>#10 #5 AND #8</td>
<td>10 9 and 5</td>
<td>S11 s6 and s10</td>
</tr>
</tbody>
</table>

27 Scopolamine (hyoscine) for preventing and treating motion sickness (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Feedback:

Comment 18/07/06

Summary

Feedback:

1. The review does not examine how the effects of scopolamine (S) vary with the route of administration and the dose, nor does it describe the time course of the effects - although data relevant to these aspects are reported in most or all the included studies.

2. Doses and the timing of observations made in the studies are not given in the Table of Characteristics of included studies. They are needed to make clear what was done. Where doses are mentioned it is not stated whether they refer to S base, or to S hydrobromide - that makes a big difference.

3. The clinical pharmacology of S needs to be considered in the discussion. Four papers with relevant data, some of which should be included in the review, are:

---

<table>
<thead>
<tr>
<th>Cochrane ENT Disorders Groups Trials Register (ProCite database)</th>
<th>Web of Science/BIOSIS Previews (Web of Knowledge)</th>
<th>Cab Abstracts (Ovid)</th>
<th>ICTRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>(motion OR car OR air OR travel OR sea OR space) AND sick* kinetosis</td>
<td>#1 TS=((car or sea or motion or air or travel or space) and sick*).tw.</td>
<td>1 ((car or sea or motion or air or travel or space) and sick*).tw.</td>
<td>motion AND sick* OR car AND sick* OR sea AND sick* OR air AND sick* OR travel AND sick* OR kinetosis</td>
</tr>
<tr>
<td></td>
<td>#2 TS=(carsick* or airsick* or seasick* or motionsick* or travelsick* or spacesick*).tw.</td>
<td>2 (carsick* or airsick* or seasick* or motionsick* or travelsick* or spacesick*).tw.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#3 TS=kinetosis</td>
<td>3 kinetosis.tw.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#4 #3 OR #2 OR #1</td>
<td>4 1 or 3 or 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#5 TS=(atrochin or atroquin or atroscine or beldavrin or buscopan or epoxytropine or euscopol or hyoscine or hyoscine or hyoscine or hyoscyline or hyosol or hyso or isoscopol or lwells or methscopolamine or oscine or pamine or scoburen or scop or scopace or scopamin or scopine or scopoderm or scopolamin or scopolamine or scopolaminhydrobromid or scopolaminium or scopos or seeren or skopolamin or tranxine or transcop)</td>
<td>5 (atrochin or atroquin or atroscine or beldavrin or buscopan or epoxytropine or euscopol or hyoscine or hyoscine or hyoscine or hyoscyline or hyosol or hyso or isoscopol or lwells or methscopolamine or oscine or pamine or scoburen or scop or scopace or scopamin or scopine or scopoderm or scopolamin or scopolamine or scopolaminhydrobromid or scopolaminium or scopolammonium or scopos or seeren or skopolamin or tranxine or transcop).tw.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#6 TS=(transderm or travacalm or triptone or (tropic adj acid) or vorigeno)</td>
<td>6 (transderm or travacalm or triptone or (tropic adj acid) or vorigeno).tw.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#7 #6 OR #5</td>
<td>7 6 OR 5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#8 #7 AND #4</td>
<td>8 4 AND 7</td>
<td></td>
</tr>
</tbody>
</table>
a) Herxheimer A. A comparison of some atropine-like drugs in man. Br J Pharmacol 1958;13,184-192. This study measured effects of three different doses of S given subcutaneously in healthy people, using an incomplete block design.

4. The review does not consider whether and how successive trials learnt [or failed to learn] from or built on earlier ones. Did they address new questions? Did the method improve? Why were they done? It would be useful to highlight this by arranging the studies in chronological rather than alphabetical order.

5. The implications for research are rather vague. It would be helpful if the authors specified more precisely what are the most urgent questions that require research.

Reply
Response to comment 1 and 2.
We have now included additional details in the 'Characteristics of included studies' that describes the timing and dosage information where available for each study. We did not do subgroup analyses of these alternative administration methods due to small numbers.
Response to comment 3.
We located each of the suggested studies however none of them were able to be included in the review due to the pre-established inclusion criteria. We have included comments on methods of delivery of scopolamine in the Discussion section of the review.
Response to comment 4.
We were unable to rearrange the order in which the studies appear in the inclusions table, however we have added a section to the Discussion which comments on when the included studies were conducted and whether any changes occurred over time.
Response to comment 5.
We have re-written this section.

Contributors
Name: Andrew Herxheimer
Email Address: a@herxheimer.net
Personal Description: Occupation Clinical Pharmacologist

WHAT'S NEW

Last assessed as up-to-date: 13 April 2011.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 May 2011</td>
<td>New search has been performed</td>
<td>We carried out new full searches in April 2011. We considered three studies for potential inclusion but none met the inclusion criteria. These studies have been added to the excluded studies table</td>
</tr>
<tr>
<td>3 May 2011</td>
<td>New citation required but conclusions have not changed</td>
<td>Change of authors.</td>
</tr>
</tbody>
</table>
HISTORY

Protocol first published: Issue 4, 2000
Review first published: Issue 3, 2004

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 May 2009</td>
<td>New search has been performed</td>
<td>Updated to include new search results to April 2009 (no new studies included)</td>
</tr>
<tr>
<td>26 October 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
<tr>
<td>23 May 2007</td>
<td>New citation required and conclusions have changed</td>
<td>Substantive amendment. Two new included studies. Six additional studies located for screening and subsequently excluded</td>
</tr>
</tbody>
</table>

CONTRIBUTIONS OF AUTHORS

Anneliese Spinks: study selection, data extraction, statistical analysis, drafting of written submissions, review development, approval of final document, guarantor of the paper.

Jason Wasiak: study selection, drafting of written submissions, review development, updating of review, approval of final document.

DECLARATIONS OF INTEREST

None known.

INDEX TERMS

Medical Subject Headings (MeSH)

Ephedrine [therapeutic use]; Histamine Antagonists [therapeutic use]; Motion Sickness [*drug therapy; prevention & control]; Muscarinic Antagonists [adverse effects; *therapeutic use]; Randomized Controlled Trials as Topic; Scopolamine Hydrobromide [adverse effects; *therapeutic use]; Treatment Outcome

MeSH check words

Adult; Child; Humans